Keloidal lesions. Hypertrophic scar
Conditions
Interventions
Intervention 1: Intervention group: Administration of 20 mg/dl intralesional TriamHexal (made in Germany) at weeks 0, 4, and 8 and administration of 2/5 mg/dl intralesional Avastin (made in Switzerlan
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: At least 1 keloidal lesion in the trunk and extremities Age 18 to 70 years old Informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Pregnancy Breastfeeding History of cardiovascular diseases Unwillingness to continue treatment Not following up Patients with severe side effects Patients who have had previous keloid therapy Infection at the injection site
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement rate according to physician's point of view. Timepoint: 4, 8, 12 weeks and then 3 months after intervention. Method of measurement: Vancuver score and photography assessment by two blinded dermatologists.;Patient satisfaction score. Timepoint: 3 months and 6 months after intervention. Method of measurement: Visual Analogue Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment side effects. Timepoint: 2 days after of each injection. Method of measurement: After the patient is instructed about possible side effects, the patient will be consulted by telephone to refer to the physician in case of severe side effects. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Bahareh Abtahi
Esfahan University of Medical Sciences
Outcome results
None listed